Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials

被引：0
|
作者：
Ritchlin, Christopher T. [1 ]
Rahman, Proton [2 ]
Helliwell, Philip S. [3 ]
Boehncke, Wolf-Henning [4 ]
McInnes, Iain [5 ]
Gottlieb, Alice B. [6 ]
Kollmeier, Alexa P. [7 ]
Shawi, May [8 ]
Zhou, Bei [7 ]
Mease, Philip J. [9 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[2] Mem Univ Newfoundland, St John, NF, Canada
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Geneva Univ Hosp, Geneva, Switzerland
[5] Univ Glasgow, Glasgow, Lanark, Scotland
[6] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
[7] Janssen Res & Dev LLC, Raritan, NJ USA
[8] Janssen Global Serv LLC, Raritan, NJ USA
[9] Univ Washington, Swedish Med Ctr, Providence St Joseph Hlth, Seattle, WA 98195 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27529
引用
收藏
页码：AB151 / AB151
页数：1
相关论文
共 50 条
  • [1] Efficacy of guselkumab using composite endpoints in patients with active psoriatic arthritis: Domain-specific efficacy from DISCOVER-1 and DISCOVER-2 phase 3 trials
    Coates, Laura C.
    Ritchlin, Christopher T.
    Gossec, Laure
    Helliwell, Philip S.
    Rahman, Proton
    Kollmeier, Alexa P.
    Karyekar, Chetan
    Sheng, Shihong
    Agarwal, Prasheen
    Mease, Philip J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB127 - AB127
  • [2] Effects of guselkumab on musculoskeletal features in patients with active psoriatic arthritis by baseline skin disease: Results from the phase 3 DISCOVER-1 and DISCOVER-2 studies
    Gottlieb, Alice B.
    Mease, Philip
    Rahman, Proton
    Kollmeier, Alexa P.
    Zhou, Bei
    McInnes, Iain B.
    Deodhar, Atul
    Helliwell, Philip
    Ritchlin, Christopher T.
    Boehncke, Wolf-Henning
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB36 - AB36
  • [3] A NOVEL PSORIATIC ARTHRITIS COMPOSITE ENDPOINT COMBINING TREATMENT TARGETS FOR SKIN AND JOINTS: POOLED RESULTS FROM THE GUSELKUMAB DISCOVER-1 AND DISCOVER-2 STUDIES
    Boehncke, W. H.
    Gottlieb, A. B.
    Soriano, E.
    Ogdie, A.
    Ziouzina, O.
    Rampakakis, E.
    Xu, X. L.
    Chakravarty, S. D.
    Shawi, M.
    Marrache, M.
    Kollmeier, A.
    Deodhar, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 261 - 262
  • [4] Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies
    Mease, Philip J.
    Helliwell, Philip S.
    Gladman, Dafna D.
    Poddubnyy, Denis
    Baraliakos, Xenofon
    Chakravarty, Soumya D.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Sweet, Kristen
    Shawi, May
    Karyekar, Chetan S.
    Deodhar, Atul
    van der Heijde, Desiree
    LANCET RHEUMATOLOGY, 2021, 3 (10): : E715 - E723
  • [5] Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2)
    Siebert, Stefan
    McInnes, Iain
    Loza, Matthew J.
    Ma, Keying
    Leander, Karen
    Lakshminarayanan, Vani
    Franks, Carol
    Cooper, Philip
    Sweet, Kristen
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [6] GUSELKUMAB INDUCES SUSTAINED REDUCTION IN ACUTE PHASE PROTEINS AND TH17 EFFECTOR CYTOKINES IN ACTIVE PSORIATIC ARTHRITIS IN TWO PHASE-3 CLINICAL TRIALS (DISCOVER-1 AND DISCOVER-2)
    Siebert, S.
    Mcinnes, I.
    Loza, M. J.
    Ma, K.
    Leander, K.
    Lakshminarayanan, V.
    Franks, C.
    Cooper, P.
    Sweet, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 144 - 145
  • [7] Guselkumab, an anti-interleukin-23p19 monoclonal antibody, modulates core psoriatic arthritis gene expression in two phase III clinical trials (DISCOVER-1 and DISCOVER-2)
    Siebert, S.
    Sweet, K. M.
    Ritchlin, C. T.
    Hsia, E. C.
    Kollmeier, A. P.
    Xu, X. L.
    Song, Q.
    Miron, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E14 - E15
  • [8] Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis
    Rahman, Proton
    Ritchlin, Christopher T.
    Helliwell, Philip S.
    Boehncke, Wolf-Henning
    Mease, Philip J.
    Gottlieb, Alice B.
    Kafka, Shelly
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Shawi, May
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Ramachandran, Paraneedharan
    Zhuang, Yanli
    McInnes, Iain B.
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (12) : 1815 - 1823
  • [9] POOLED SAFETY RESULTS FROM TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 1 YEAR
    Ritchlin, C. T.
    Rahman, P.
    Helliwell, P.
    Boehncke, W. H.
    Mcinnes, I.
    Gottlieb, A. B.
    Kafka, S.
    Kollmeier, A.
    Hsia, E. C.
    Xu, X. L.
    Shawi, M.
    Sheng, S.
    Agarwal, P.
    Zhou, B.
    Ramachandran, P.
    Mease, P. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1300 - 1301
  • [10] GUSELKUMAB TREATMENT MODULATES CORE PSORIATIC ARTHRITIS GENE EXPRESSION IN TWO PHASE 3 CLINICAL TRIALS (DISCOVER-1 AND-2)
    Siebert, S.
    Sweet, K.
    Ritchlin, C. T.
    Hsia, E. C.
    Kollmeier, A.
    Xu, X. L.
    Song, Q.
    Miron, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 312 - 312
12345